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ABSTRACT 
Linezolid is a weak, non-selective inhibitor of monoamine oxidase (MAO). It can inhibit the breakdown of the tyramine by MAO in the gut and can 
also potentiate the effect of tyramine at nerve endings, thereby causing an increase in blood pressure. We encountered a neonate who developed 
acute hypertensive episode after simultaneous administration of dopamine and linezolid. A 25 w preterm neonate was admitted in NICU (Neonatal 
Intensive Care Unit) with complaints of Patent Ductus Arteriosus and respiratory infection. Linezolid infusion 6.5 mg every 8 h over 30 min (7 am, 
3pm, 11 pm) was added after confirmation of gram-positive cocci (Staphylococcus epidermis) growth. Inj. Dopamine 20 mcg/kg/min was started 
for derangement in blood pressure 52/28 mm Hg (Mean blood pressure 43) at 5 pm. The baby developed acute hypertensive episode at 5.30 pm for 
which dopamine was withdrawn immediately. The half-life of Linezolid is 5.6 h in preterm baby, and that of Dopamine is 2 min. Since the probability 
of peak concentration for both the administered drugs was around the same time period, the baby developed acute hypertensive episode. So the 
combination of Linezolid with Dopamine should be avoided if possible or the dosage interval has to be extended to minimize the adverse reaction. 
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INTRODUCTION 
A drug interaction is defined as the “pharmacologic or clinical 
response to the administration of a drug combination different from 
that anticipated from the known effects of the two agents”. The 
interaction may result in a change in the nature or type of response 
to a drug (i.e., pharmacodynamic interaction), or a change in the 
magnitude or duration of response to a drug (i.e., pharmacokinetic 
interaction) [1]. 
Linezolid is an oxazolidinone antibacterial agent that has a unique 
mechanism of inhibition of bacterial protein synthesis [2]. It is also a 
weak, reversible non-selective monoamine oxidase inhibitor (MAOI) 
[3-12]. It can inhibit the breakdown of the tyramine by MAO in the 
gut and can also potentiate the effect of tyramine at nerve endings, 
thereby causing an increase in blood pressure [6-13]. Studies in 
adults recommended that it should not be taken while administering 
another MAOI or within 2 w of stopping another MAOI, unless close 
observation and blood pressure monitoring are possible. It should 
be avoided in those receiving Selective Serotonin Reuptake 
Inhibitors (SSRIs), 5HT1
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 (Serotonin) agonist, Tricyclic Anti-
depressant (TCA), sympathomimetics, dopaminergic, buspirone, 
pethidine and possibly other opioid analgesics [5]. The usual dose 
and administration for Neonate is 10 mg/kg per dose every 8 h by IV 
infusion over 30 min to 120 min and for preterm newborns less than 
1 w of age: 10 mg/kg per dose every 12 h. Oral dosing is the same as 
IV [2, 14-15]. 
A male preterm baby of 25 w gestational age, weighing 800 gm was 
born to a cervical incompetence mother after two successive 
spontaneous abortion/miscarriage. The baby was on a ventilator for 
2 w and later Ibuprofen was given after extubation. The baby was 
diagnosed to have Patent Ductus Arteriosus and respiratory 
infection and was on ampicillin, amikacin, meropenem and 
vancomycin from outside hospital. Due to persistent lung 
congestion, the baby was reintubated and later came here for further 
management. 
The baby was admitted in the Neonatal Intensive Care Unit (NICU) of 
Neonatology Department, Amrita Institute of Medical Sciences. 
Empirically the baby was started on Inj. Meropenem 25 mg every 8 
hourly, Inj. Cefoperazone+Salbactum 25 mg 8 hourly, Inj. 
Amphotericin 1 mg every 24 hourly and later Inj. Caffeine 3.5 mg 
every 24 hourly was added for apnea at 6 pm. The culture from 
Endotracheal Suction tube was found to have Burkholderia Cepacia, 
which was resistant to Piperacillin and sensitive to Ceftazidime, 
Meropenem, and Trimethoprim+Sulfamethoxazole. Arterial blood 
culture detected Staphylococcus epidermidis (Coagulase-negative) and 
was resistant to Penicillin G, Cloxacillin/Oxacillin, Rifampicin and 
Ofloxacin but sensitive to Vancomycin, Cotrimoxazole, Teicoplanin, 
and Linezolid. Salbutamol Nebulisation was given on eighth day every 
6 hourly and inj. Fluconazole was also added on next day. 
From the 5th day of admission Inj. Linezolid 6.5 mg every 8 h (7 am, 3 
pm and 11 pm) was infused over 30 min. On 11th day of admission 
(39th
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 day of life) the baby developed deranging heart rate of 16 
beats/min and blood pressure of 52/28 mm Hg, (Mean Blood 
Pressure-43) for which Inj. Dopamine 20 mcg/kg/min was started at 
5 pm. The baby developed acute hypertensive episode (99/59 mm 
Hg and Mean Blood Pressure 78) at 5.30 pm. Subsequently 
Dopamine was withdrawn and blood pressure monitored. For a low 
birth weight infant, the normal systolic range is 50-62 mmHg, and 
the diastolic range is 26-36 mmHg. It was advised that combination 
of Linezolid with Dopamine should be avoided if possible. 
Linezolid interacts with Dopamine to cause acute hypertensive 
episodes. The half-life of dopamine is 2 min and that of Linezolid is 
5.6 h for preterm. For linezolid, the time to reach peak concentration 
was after 1-2 h [14]. So after the completion of Linezolid infusion at 
3.30 pm its peak concentration will be reached around 5.30 pm 
during which the interaction has been encountered.“Linezolid is a 
reversible non-selective MAOI. Administration of MAOI causes 
accumulation of Norepinephrine within adrenergic neurons 
including sympathetic neurons that innervate arterial blood vessels. 
Under such circumstances, the administration of a sympathomimetic 
agent can cause the release of the stored excess NE and 
subsequently exaggerated constriction of blood vessels and rise in 
blood pressure. Data demonstrate that the two medications may 
interact with each other in a clinically significant manner. A patient-
specific assessment must be conducted to determine whether the 
benefits of concomitant therapy outweigh the risk. Specific actions 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 1, 2016 
Alex et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 467-468 
 
468 
must be taken in order to realize the benefits or minimize the 
toxicity resulting from the concomitant use of the agents. These 
actions may include aggressive monitoring, empiric dosage changes 
and choosing alternative agents” [15]. 
CONCLUSION 
Since the probability of acute hypertensive episode may be due to 
drug interaction, most of the catecholamines are not reliable for co-
administering with Linezolid. In such cases Dopamine should start at 
a low dose or if the possible spacing between the interacting drugs 
should be prolonged to minimize anticipated toxicity. 
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